Abstract
Background Frontotemporal dementia is the second most common form of early onset dementia (< 65 years). Despite this there are few known disease modifying factors. The anterior cingulate is a focal point of pathology in behavioural variant frontotemporal dementia. Sulcation of the anterior cingulate is denoted by the presence of a paracingulate sulcus, a tertiary sulcus developing, where present during the third gestational trimester and remaining stable throughout life. This study aims to examine the impact of right paracingulate sulcal presence on the expression and prognosis of behavioural variant Frontotemporal Dementia.
Methods This retrospective analysis drew it’s population from two clinical samples recruited from memory clinics at University Hospitals in The United States of America and The Netherlands. Individuals with sporadic behavioural variant Frontotemporal Dementia were enrolled between 2004 and 2022 and followed up for an average of 7.71 years. T1-MRI data were evaluated for hemispheric paracingulate sulcal presence in accordance with an established protocol by two blinded raters. Outcome measures included age at onset, survival, cortical thickness, and Frontotemporal Lobar Degeneration-modified Clinical Dementia Rating determined clinical disease progression.
Results The study population consisted of 186 individuals with sporadic behavioural variant Frontotemporal Dementia, (113 males and 73 females) mean age 63.28 years (SD 8.32). The mean age at onset was 2.44 years later in individuals possessing a right paracingulate sulcus (60.2 years (SD 8.54)) versus individuals who did not (57.76 (8.05)), 95% CI >0.41, P = 0.02. Education was not associated with age at onset (β = -0.05, P=0.75). Presence of a right paracingulate sulcus was associated with a 119% increased risk of death per year after age at onset (HR 2.19, CI [1.21 - 3.96], P<0.01), whilst the mean age at death was similar for individuals with a present and absent right paracingulate sulcus (P = 0.7). Right paracingulate sulcal presence was not associated with baseline cortical thickness.
Conclusion Right paracingulate sulcal presence is associated with disease expression and survival in sporadic behavioural variant Frontotemporal Dementia. Findings provide evidence of neurodevelopmental brain reserve in behavioural variant Frontotemporal Dementia which may be important in the design of trials for future therapeutic approaches.
Competing Interest Statement
OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Fujirebio, Genentech, Novartis, Novo Nordisk, Roche, and Siemens.
Clinical Protocols
https://aspredicted.org/SKM_6C1
Funding Statement
Funding Work at the Clinical Memory Research Unit Lund University was supported by The Swedish Research Council (2022-00775) The Knut and Alice Wallenberg foundation (2017-0383) The Strategic Research Area MultiPark (Multidisciplinary Research in Parkinsons disease) at Lund University the Swedish Alzheimer Foundation (AF-980907) The Swedish Brain Foundation (FO2021-0293) The Parkinson foundation of Sweden (1412/22) The Cure Alzheimers fund The Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse The Skane University Hospital Foundation (2020-O000028) Regionalt Forskningsstod (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080) Additional funding to A.F.S. was provided by The Swedish Society for Medical Research and The Bente Rexed Gersteds Foundation for Brain Research. L.H. A.F.S. and O.L. are all supported by The Schorling foundation. L.H is funded primarily by the Swedish federal government under the ALF agreement (ALF ST 2021-2023/4-43338). Work at the University of Pennsylvania was supported by NIH grants 5P01AG066597-03 6308 (CM) 5R01NS109260-04 (DI) and 1R01AG076832-01A1 (LM). The funding sources had no role in the design and conduct of the study; in the collection analysis interpretation of the data or in the preparation review or approval of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical Ethics Committee of the Amsterdam UMC, VUmc, Amsterdam, Holland and The Ethics Committee of University of Pennsylvania Institutional Review Board (IRB)gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
